I’m hiring for Neurology and Clinical Neurophysiology position in NY and other states. Position is available on FT, PT, or freelance bases. Physician will work in a team setting and independently. Physicians must be comfortable seeing adults and children. Neurology Physician must be skilled in state-of-the-art advanced diagnostic tests and evaluations like:
nerve conduction studies (NCS), EEG, EMG and NCV tests
evoked potential studies (VEP, BAER, SSEP)
carotid and transcranial Doppler studies
innovative and individualized approaches to care, like BOTOX injections for headaches and other conditions
facet joint blocks
sacroiliac joint blocks and injections
epidural steroid injections
radiofrequency facet joint ablation
TMJ injections and carpal tunnel steroid injection
Neuropsychologist Physician will be working with kids and adults with the following conditions:
PANS / PANDAS
Ideal candidate will be familiar with QEEG, TMS, Neurofeedback and other modalities.
Training is also available for potential candidate.
Summary: The formation of prefrontal cortex dendritic spine formation sustains the remission of depressive related symptoms and behaviors following ketamine treatment by restoring lost spines.
Researchers have identified ketamine-induced brain-related changes that are responsible for maintaining the remission of behaviors related to depression in mice — findings that may help researchers develop interventions that promote lasting remission of depression in humans. The study, funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health, appears in the journal Science.
Major depression is one of the most common mental disorders in the United States, with approximately 17.3 million adults experienced a major depressive episode in 2017. However, many of the neural changes underlying the transitions between active depression, remission, and depression re-occurrence remain unknown. Ketamine, a fast-acting antidepressant which relieves depressive symptoms in hours instead of weeks or longer, provides an opportunity for researchers to investigate the short- and long-term biological changes underlying these transitions.
“Ketamine is a potentially transformative treatment for depression, but one of the major challenges associated with this drug is sustaining recovery after the initial treatment,” said study author Conor Liston, M.D., Ph.D., of Weill Cornell Medicine, New York City.
To understand mechanisms underlying the transition from active depression to remission in humans, the researchers examined behaviors related to depression in mice. Researchers took high-resolution images of dendritic spines in the prefrontal cortex of mice before and after they experienced a stressor. Dendritic spines are protrusions in the part of neurons that receive communication input from other neurons. The researchers found that mice displaying behaviors related to depression had increased elimination of, and decreased the formation of, dendritic spines in their prefrontal cortex compared with mice not exposed to a stressor. This finding replicates prior studies linking the emergence of behaviors related to depression in mice with dendritic spine loss.
In addition to the effects on dendritic spines, stress reduced the functional connectivity and simultaneous activity of neurons in the prefrontal cortex of mice. This reduction in connectivity and activity was associated with behaviors related to depression in response to stressors. Liston’s group then found that ketamine treatment rapidly restored functional connectivity and ensemble activity of neurons and eliminated behaviors related to depression. Twenty-four hours after receiving a single dose of ketamine, mice exposed to stress showed a reversal of behaviors related to depression and an increase in dendritic spine formation when compared to stressed mice that had not received ketamine. These new dendritic spines were functional, creating working connections with other neurons.
The researchers found that while behavioral changes and changes in neural activity in mice happened quickly (three hours after ketamine treatment), dendritic spine formation happened more slowly (12-24 after hours after ketamine treatment). While further research is needed, the authors suggest these findings might indicate that dendritic spine regrowth may be a consequence of ketamine-induced rescue of prefrontal cortex circuit activity.
Although dendritic spines were not found to underly the fast-acting effects of ketamine on behaviors related to depression in mice, they were found to play an important role in maintaining the remission of those behaviors. Using a new technology developed by Haruo Kasai, Ph.D., and Haruhiko Bito, Ph.D., collaborators at the University of Tokyo, the researchers found that selectively deleting these newly formed dendritic spines led to the re-emergence of behaviors related to depression.
“Our results suggest that interventions aimed at enhancing synapse formation and prolonging their survival could be useful for maintaining the antidepressant effects of ketamine in the days and weeks after treatment,” said Dr. Liston.
“Ketamine is the first new anti-depressant medication with a novel mechanism of action since the 1980s. Its ability to rapidly decrease suicidal thoughts is already a fundamental breakthrough,” said Janine Simmons, M.D., Ph.D., chief of the NIMH Social and Affective Neuroscience Program. “Additional insights into ketamine’s longer-term effects on brain circuits could guide future advances in the management of mood disorders.”
ABOUT THIS NEUROSCIENCE RESEARCH ARTICLE
Source: NIH/NIMH Media Contacts:
Nick Miller – NIH/NIMH Image Source:
The image is in the public domain.
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
The neurobiological mechanisms underlying the induction and remission of depressive episodes over time are not well understood. Through repeated longitudinal imaging of medial prefrontal microcircuits in the living brain, we found that prefrontal spinogenesis plays a critical role in sustaining specific antidepressant behavioral effects and maintaining long-term behavioral remission. Depression-related behavior was associated with targeted, branch-specific elimination of postsynaptic dendritic spines on prefrontal projection neurons. Antidepressant-dose ketamine reversed these effects by selectively rescuing eliminated spines and restoring coordinated activity in multicellular ensembles that predict motivated escape behavior. Prefrontal spinogenesis was required for the long-term maintenance of antidepressant effects on motivated escape behavior but not for their initial induction.
Ketamine is used for starting and maintaining anesthesia and induces a trance-like state while providing pain relief, sedation, and memory loss. It can cause confusion and hallucinations as it wears off. Discovered in 1962 it was used in the Vietnam War due to its safety and is on the WHO’s list of essential medicines.
It’s also used as a recreational drug in raves and as a club drug. Due to this, it’s a schedule III substance in the U.S.
Dr. Jari Laukkanen on Sauna Use For the Prevention of Cardiovascular & Alzheimer’s Disease
This podcast features Jari Laukkanen, M.D., Ph.D., a cardiologist and scientist at the Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio. Dr. Laukkanen has been conducting long-term trials looking at the health effects of sauna use in a population of over 2,000 middle-aged men in Finland. The results? Massive reductions in mortality and memory disease in a dose-response fashion at 20-year follow-up. In this almost 25-minute episode, we talk about…
00:00:37 – The association between sauna use and fatal cardiovascular outcomes
00:00:37 – The inverse association between cardiovascular-related deaths and all-cause deaths.
00:02:00 – How men that used the sauna 2-3 times per week had a 27% lower cardiovascular-related mortality than men that used the sauna 1 time per week
00:02:15 – How men that used the sauna 4-7 times per week had a 50% lower cardiovascular-related mortality than men that used the sauna one time per week.
00:02:50 – The confounding factors Dr. Laukkanen and his colleagues had to adjust for, such as physical exercise, cholesterol, obesity, smoking, alcohol consumption, socioeconomic status.
00:03:26 – The various types of cardiac-related deaths their reductions were shown in, including coronary artery disease, sudden cardiac death and more.
00:05:00 – How one of the major mechanisms by which sauna use improves heart health is by reducing blood pressure and incident hypertension.
00:05:40 – The mechanisms by which the sauna lowers blood pressure, which can occur via balancing of the autonomic nervous system, improvements in blood vessel function, decreases in arterial stiffness and compliance of arteries.
00:06:17 – The increases in heart rate seen with sauna use that make it similar to moderate aerobic exercise in some ways (up to 150 beats/min!).
00:06:56 – How time spent in the sauna was one of the more important factors for risk reduction with at least 20 minutes per session in a 174 F (79C) 4-7 times per week being a “sweet spot.”
00:09:29 – The inverse, dose-response relationship between sauna use and all-cause mortality: 24% for 2-3 times per week, 40% for 4-7 times.
00:10:00 – His newest study that now shows a reduction in risk in a similar dose-response fashion for dementia and Alzheimer’s disease by around 65% for the most frequent sauna users.
00:10:18 – The way sauna use increases heat shock proteins which repair damaged proteins and prevent protein aggregates and how this could end up being at least one potential molecular mechanism at play.
00:13:03 – How sauna use increases growth hormone by 200-330%.
00:14:10 – The patterns of sauna use and especially whether to sauna before or after you weight train.
00:15:55 – The effect of sauna on mood which may be from improvements in cardiorespiratory fitness and possibly endorphins as well.
00:18:39 – How sauna improves heart rate variability.
00:20:04 – Cold-water immersion after sauna and a few cautionary words for extreme contrast therapy in people with a pre-existing heart condition that is currently unstable.
Further, Dr. Mary Shackelton, MPH, ND talks about skin as a pathway for detoxification and how important it is to sweat on a weekly basis. Infrared saunas are one of the most effective ways of releasing toxins from deep within one’s tissues.
https://madisonarealymesupportgroup.com/2018/01/03/the-invisible-universe-of-the-human-microbiome-msm/ Briefly, MSM stands for Methylsulfonylmethane and is 34% sulfur by weight. Sulfur plays a crucial role in detoxification and is an important antioxidant for producing glutathione. If you aren’t getting enough sulfur, glutathione can not work. Even if you have a diet rich in sulfur (think cabbage, onions, garlic, broccoli, etc – essentially the stinky veggies – and many other food items as well) your body still could use supplementation.
https://madisonarealymesupportgroup.com/2019/03/14/melatonin-benefits-uses/ Besides helping sleep, melatonin is known for protecting the brain. Research has shown starting to supplement in middle age protects against Alzheimer’s, reduces the risk of Parkinson’s, shrinks the size of the infarct area in a stroke, minimizes brain swelling & dysfunction after head injury, and increases the “longevity protein” SIRT1.
In certain regions of New York state, USA, Ixodes scapularis ticks can potentially transmit 4 pathogens in addition to Borrelia burgdorferi: Anaplasma phagocytophilum, Babesia microti, Borrelia miyamotoi, and the deer tick virus subtype of Powassan virus. In a prospective study, we systematically evaluated 52 adult patients with erythema migrans, the most common clinical manifestation of B. burgdorferi infection (Lyme disease), who had not received treatment for Lyme disease. We used serologic testing to evaluate these patients for evidence of co-infection with any of the 4 other tickborne pathogens. Evidence of co-infection was found for B. microti only; 4–6 patients were co-infected with Babesia microti. Nearly 90% of the patients evaluated had no evidence of co-infection. Our finding of B. microti co-infection documents the increasing clinical relevance of this emerging infection.
The fact they only found 1 coinfection isn’t a shocker. Some of the sickest patients NEVER test positive because of dysfunctional immune systems. I’m not sure when they are ever going to think of using a provoking agent to stir the pathogens up, kill them, and then get the dead pieces and parts into the blood where this abysmal testing for antibodies can be picked up, but I’m not going to hold my breath. This study seriously makes me want to bang my head against the wall. They’ve learned nothing and continue to do the same exact things.
The only thing they got right was the, “increasing clinical relevance of this emerging infection,” but I’ve got news for them: this is just the tip of the iceberg.
They need to get Dr. Breitshwerdt in on these studies and allow him to test the patients for Bartonella using the tests he’s developed. They also need to use provoking agents and then test, or use direct testing, and to drop the EM rash criteria like a bad habit.
GLA’S PIONEERING RESEARCH FUNDING STRATEGY RESULTS IN PROMISING OUTCOMES THAT HELP PATIENTS SUFFERING FROM LONG-TERM LYME DISEASE
STAMFORD, CONN (April 12, 2019)—Global Lyme Alliance’s commitment to identify and fund innovative and promising Lyme disease research is unrivaled. A vital component to GLA’s leadership role in Lyme disease research is its success with early-stage funding. Discovering and supporting researchers who are new to Lyme but bring years of relevant disease work or are at the beginning of their careers, helps distinguish GLA’s approach to finding the evidence-based answers that will ultimately help patients.
In 2009, on a limited research budget, GLA had decided to proactively recruit scientists and fund research in new areas to further the understanding of Borrelia burgdorferi (the Lyme bacteria) that could lead to an improved diagnostic test and ultimately, a cure, for Lyme disease. GLA’s objectives were to:
determine if the antibiotic evading technique of bacteria, like Escherichia coli, is being used by the Lyme bacteria and therefore explain the typical patient experience of symptom improvement followed by symptom relapse
determine if such persistent or dormant cells were protected within biofilms
identify existing drugs from a vast FDA library and find novel new treatments to eliminate persister (non-growing) and growing Lyme bacteria which could be a cure
identify the surface proteins of the persister form of the bacteria to improve the current diagnostic tests. The first step in achieving these objectives was to fund a study conducted by Ying Zhang, M.D. at Johns Hopkins University in early 2010, to see if the Lyme bacteria could form persister or dormant cells in the test tube; and if they did, to proceed with the other aforementioned aims
Based on early findings of the Zhang/Johns Hopkins study that showed that the Lyme bacteria could ‘morph’ into persisters, GLA then recruited Kim Lewis, Ph.D., Director of the Antimicrobial Discovery Center at Northeastern University, who is an expert in the area of bacterial persistence and antibiotic tolerance. GLA worked with Dr. Lewis on developing a multi-year study design and agreed to fund it. This study would ultimately confirm the ability of Lyme organisms to become persisters and went on to then find existing and new drugs to kill these persister (non-growing) forms. Both Northeastern and Johns Hopkins were running parallel, independent experiments and drug discovery protocols backed by GLA.
By 2018, Dr. Ying Zhang and his team at Johns Hopkins made significant strides:
Confirmed the existence in vitro of the dormant, persister Lyme bacteria
Showed how the Lyme bacteria goes dormant and changes its protein composition and shape when exposed to antibiotics and then grows again when antibiotic treatment is stopped
Identified its protein components and a new diagnostic tool to recognize persistence in patients
Used high-throughput drug discovery and drug efficacy testing programs
Identified a powerful combination of Daptomycin + Cefuroxime + Doxycycline to eliminate growing and non-growing forms of the bacteria and identified essential oils from spice and culinary herbs (g., oregano, cinnamon bark, and clove bud) which also serve to eliminate persister bacteria as well as biofilm-like forms
By 2018: Dr. Kim Lewis and his team at Northeastern University, independently, also made considerable findings:
Confirmed the existence in vitro of the dormant, persister Lyme bacteria
Showed how the Lyme bacteria goes dormant when exposed to antibiotics and then springs back to a form capable of growing again
Using a separate drug screening tool, identified Daptomycin, Mitomycin C (an anticancer agent) and Ceftriaxone as a possible drug combination to eliminate dormant and growing cells
Discovered through Dr. Lewis’ pipeline discovery program that Disulfiram, used for treating alcoholism, was extremely effective in culture and in mice in to killing burgdorferi in all forms
Discovered an antibiotic through his proprietary approach to screen soil bacteria, known as Hygromycin A that could kill the Lyme bacteria in vitro and in mice
Proved that in vitro, Vancomycin was more powerful in clearing all forms of the Lyme bacteria than Doxycycline
The complete path from initial seed funding to results that will impact patients follows.
GLA Initial Seed Funding (2013)
GLA is the first to identify Dr. Lewis as a scientific expert looking at bacterial persister cells, antibiotic tolerance, and novel therapies who could apply his knowledge to the study of Lyme disease
GLA helps design and funds Dr. Lewis’ multi-year study, “Persister Cells and Antibiotic Tolerance in Bb” to investigate whether burgdorferi forms antibiotic-tolerant persister forms
GLA Annual Lyme Disease Research Symposium (2014)
In 2014, through regular progress reports to GLA Scientific Advisory Board and presenting at GLA’s annual Lyme Disease Research Symposium, Dr. Lewis shares his initial findings from GLA-funded study. At the Symposium are other top scientists, including Dr. Brian Fallon, Dr. Armin Alaedini, and Dr. John Aucott
Lewis finds that B. burgdorferi can go dormant to evade antibiotics and then restart replication once antibiotics are removed. He had then performed an initial screen of FDA drugs for novel compounds that could target persister forms of the Lyme bacteria
Lewis was honored at Global Lyme Alliance Greenwich Gala, along with Ying Zhang, M.D., Ph.D., of Johns Hopkins University for their work in discovering Borrelia persisters
Published Findings (2015): The Lyme bacteria morphs to evade antibiotics
Lewis publishes landmark paper on persisters in Antimicrobial Agents and Chemotherapy, “Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells”, based on GLA funding from 2013. He showed that antibiotics killed most lab-grown B. burgdorferi, with a small surviving population that tolerated drug treatment. His team found that Mitomycin C efficiently killed persisters
Lewis noted that persisters play dead and then reawaken once treatment is completed in the context of recurrent urinary tract infections. “They start multiplying again, he explains, “and you get this relapsing, chronic infection.” It is possible a similar situation and explanation exists for chronic Lyme disease; however, more research is needed to test this hypothesis
In 2016, GLA funds Dr. Lewis’ well-regarded study “Discovery of new antibiotics and combinations”
Initial findings include results using Disulfiram (an FDA-approved drug for the treatment of chronic alcoholism and Hygromycin A (an antibiotic derived from soil bacteria)
In 2017 and 2018, a top Lyme-treating physician starts implementing Dr. Lewis’ findings using Disulfiram to treat post-treatment Lyme disease patients. To date, on a limited number of patients, Disulfiramis proving very promising
GLA-funded researcher and Lyme-treating physician Dr. Brian Fallon of Columbia University designs a clinical study to determine therapeutic efficacy of Disulfiram in 2019
Thanks to four years of financial backing by GLA, Dr. Lewis is able to deliver ground-breaking discoveries in Lyme disease, in particular, persisters and novel treatments, enabling him to attract attention from additional private foundation donors. This enables Dr. Lewis greater opportunity to investigate new therapies for chronic Lyme patients
Published Findings (2018): Vancomycin is the strongest antibiotic in treating Lyme disease
In 2018, Dr. Lewis publishes important paper on novel therapies in Antimicrobial Agents and Chemotherapy, “Identifying Vancomycin as an Effective Antibiotic for KillingBorrelia burgdorferi“, based on GLA funding.
Lewis’ team found that Vancomycin was effective against in vitro cultures of growing B. burgdorferi. However, this class of drugs is not expected to work on stationary persister cells, in which growth is very slow, and cell wall synthesis is expected to be minimal. Unexpectedly, when tested on stationary B. burgdorferi, they found that cell wall synthesis still occurred, and could be blocked by Vancomycin.
To extend their studies to an in vivo model, the group treated burgdorferi-infected, immunodeficient mice for five days. They found that Vancomycin and Ceftriaxone each completely blocked bacterial growth, compared with partial eradication by Doxycycline. These studies suggest that more effective antimicrobial drugs, used early in infection, may prevent or reduce the occurrence of persisting infection.
Clinical Trials & Helping Patients (2019)
In 2019, GLA helps facilitate clinical trials leveraging Dr. Lewis’ findings with respected Lyme-treating physicians. Clinical trials performed under the guidance of GLA’s rigorous peer-reviewed process will ensure valid results, to most effectively impact patients.
Lyme disease is extremely complex, and the challenge to understand it and ascertain how to most successfully treat patients impacted by it is a herculean task. Through an aggressive and innovative research strategy, backed by a world-renowned Scientific Advisory Board and top-notch in-house science team, GLA is finding the answers.
About Global Lyme Alliance Global Lyme Alliance is the leading 501(c)(3) organization dedicated to conquering Lyme and other tick-borne diseases through research, education and awareness. GLA has gained national prominence for funding some of the most urgent and promising research in the field, while expanding education and awareness programs for the general public and physicians. We support those around the globe in need of information about tick-borne diseases. Learn more at GLA.org.
Credit should be given where credit is due. GLA is kicking butt in the world of Lyme/MSIDS research.
Currently, Disulfiram is being used on numerous Lyme/MSIDS patients in Mexico and many more in the U.S. with pretty astounding results. The herxes can be surreal so it takes an experienced practitioner, but, it has action against malaria, HIV, cancer and Lyme(borrelia):
Scroll to 39:00. Dr. Lewis states they were looking for compounds specific to Bb, so it wouldn’t be toxic. Disulfiram is selective for Bb and blew Vancomycin, Ceftriaxone, and Doxycycline out of the water and is very safe. It completely sterilizes Bb and kills persisters in vivo.
Disulfiram has a long half-life of 60-120 hours, crosses the blood brain barrier, is slowly absorbed in the digestive tract and is also eliminated slowly making effects last up to two weeks after initial intake.
Do not self-treat. Talk to your practitioner about these findings and work with him/her. While Disulfiram (Antabuse) is cheap, it can cause vast die-off and an inflammatory response that could put you in the ER.
Lyme disease is primarily transmitted by ticks; that much most people know. The link between the words ‘Lyme’ and ‘ticks’ is cemented in the public consciousness, so much so that in 2018, many will instinctively conjure images of ticks when they hear or read something concerning Lyme disease. This is certainly progress. The enigmatic disease was only discovered a mere 43 years ago, although it has been around for centuries. Since its discovery in the town of Old Lyme, Connecticut, the disease has had a hard time being taken seriously, or at least being considered as the debilitating threat it undoubtedly is. Now that Lyme is finally becoming more visible in the mainstream medical community, patients and doctors alike are looking at ways it can be transmitted. One of the areas up for discussion is the possibility of sexual transmission.
Many severe and extreme conditions can be transmitted sexually, and everyone is aware of the dangers of prominent STDs like AIDS, HIV, syphilis, gonorrhoea and herpes. But could Lyme disease also join the line-up of threats? It was previously thought that any type of human-to-human Lyme transmission was impossible, and only specific types of tick could spread the disease. Borrelia burgdorferi is the bacteria responsible for causing Lyme; it’s carried by deer ticks in North America, and sheep ticks in Europe. It is estimated that as many as one in three ticks are contaminated with Borrelia, making the likelihood of catching Lyme in tick-populated areas quite high. Many people dismiss Lyme disease as they believe it’s easy to tell if you’ve been bitten by a tick or not. However, it is not altogether straightforward. Ticks will often seek out sheltered or hard-to-reach places on the human body before biting, and their saliva is laced with a paralytic agent that further minimises the risk of detection.
The appearance of a distinctive bullseye rash is one of the most concrete indicators of Lyme disease, although it can be quite hard to spot, and never appears in the first place in a minority of cases. This rash is accompanied by flu-like symptoms as the disease spreads in its acute stage. When these symptoms subside, the bacteria settle into the body, and the condition mutates into its chronic stage, which is notoriously hard to both diagnose and treat, and remains a point of contention between Lyme experts and other medical professionals. If the offending bacteria remains in a person’s system for many years, then it’s logical to assume that they can potentially transmit Lyme disease to their sexual partner(s) at any point during the prolonged infection. Therefore, it’s crucial to know if and how this type of transmission is possible.
According to the CDC (the Centres of Disease Control and Prevention), the case is crystal clear: their website officially states that ‘there is no credible scientific evidence that Lyme disease is spread through sexual contact’, going so far as to say that ‘the biology of the Lyme disease spirochete is not compatible with this route of exposure’. However, the CDC hasn’t got a great track history of Lyme expertise. Their position on the chronic form of Lyme is still a grey area at best, and their website also states that, in relation to the transmission of Lyme disease from mother to child during pregnancy, ‘no negative effects on the foetus have been found’. In fact, the transmission of Lyme during pregnancy is well-documented by Lyme experts and researchers, and although it’s a rare scenario, it is still possible.
So how do the experts see it? Dr. Carsten Nicolaus, head of Lyme specialists BCA-clinic in Augsburg, thinks that the question is not easily answered, and although it’s a probability, the risk seems very low. He cites a study conducted by Marianne Middelveen and Dr. Ray Stricker in 2014, which confirmed the presence of Borrelia burgdorferi in the genital secretions of Lyme-positive heterosexual couples. In one case, a couple was found to secrete an identical strain of Lyme spirochete in their separate samples, strongly indicating that the bacteria can be transmitted through unprotected sex. However, the study conducted is far too small to be of any diagnostic use; although the findings are interesting and alarming, more research and studies need be conducted to produce a concrete answer.
In theory, certainly, sexual transmission of Lyme disease is possible. The corkscrew-shaped Lyme spirochete shares many traits with Treponema pallidum, the microbe that causes syphilis. The latter is well-versed in the sexual transmission pathway, and has honed the method to near perfection. Borrelia has repeatedly been shown to be both opportunistic and insidious in the way it infects and survives in its host; it follows that if the opportunity for a new method of infection arose, it would almost certainly take it. As Lyme disease becomes more visible all over the world, it is important to remember that we know startlingly little about it, in comparison to other disorders. As such, it is crucial that meticulous study and tests continue, so we can rule out certain methods of transmission, or devise new ways to fight them.
Although this was written 4 months ago, it still demands an answer.
Isn’t it interesting that the small 2014 study barely raised eye-brows except for in the Lyme world? That should tell you something right away.
Authorities don’t want to know the answer to this question because first they’d have to admit stupidity & that they were wrong, and second, they’d have to do something about it….and heaven forbid either of those two things happen.
I’m quite open about the fact I believe I got this STD from my infected husband. All my initial symptoms were gynecological, it’s just I didn’t know anything about Lyme/MSIDS at the time. I went down the rabbit-hole of transmission fairly quickly in my journey due to my own case and I write about it, with tons of links to studies and experts disagreeing with the accepted narrative here: https://madisonarealymesupportgroup.com/2017/02/24/pcos-lyme-my-story/
Nothing is going to happen unless we demand it to happen. I find it highly interesting that at the first whiff of Zika being sexually transmitted, authorities followed through and it was the shot heard around the world – even though mosquitoes can’t even carry it in Wisconsin and many, many other states.
Here’s the map of places in the U.S. where the mosquitoes capable of transmitting Zika live:
In total – 7 types of ticks spreading deadly diseases in every single state in the U.S. but we know more about a tropical disease that in 80% of those who contract it have ZERO symptoms, and 1 out of 5 will have mild symptoms that last a week. https://madisonarealymesupportgroup.com/2016/12/21/how-zika-got-the-blame/. Call me crazy, but the disparity of risk between the two diseases couldn’t be greater.
Not to mention that migrating birds are transporting ticks worldwide: